Gil Roth05.01.12
Parexel 3Q
3Q Revenues*: $356 million (+18%)
3Q Earnings: $22.9 million (+46%)
YTD Revenues*: $1.0 billion (+11%)
YTD Earnings: $45.3 million (-10%)
* Consolidated service revenues only
Comments: Backlog at the end of the quarter was approximately $4.2 billion (+33% year-over-year). Reported backlog included gross new business wins of $1.1 billion, cancellations of $263.3 million, and a positive impact from foreign exchange rates, and other small adjustments of $44.3 million. The net book-to-bill ratio was 2.23 in the quarter. Revenues for the quarter were $263.4 million in Clinical Research Services (CRS), $43.3 million in Parexel Consulting and Medical Communications Services (PCMS), and $49.3 million in Perceptive Informatics. New business gains have led to increased hiring and other expenditures, reducing operating margins.
3Q Revenues*: $356 million (+18%)
3Q Earnings: $22.9 million (+46%)
YTD Revenues*: $1.0 billion (+11%)
YTD Earnings: $45.3 million (-10%)
* Consolidated service revenues only
Comments: Backlog at the end of the quarter was approximately $4.2 billion (+33% year-over-year). Reported backlog included gross new business wins of $1.1 billion, cancellations of $263.3 million, and a positive impact from foreign exchange rates, and other small adjustments of $44.3 million. The net book-to-bill ratio was 2.23 in the quarter. Revenues for the quarter were $263.4 million in Clinical Research Services (CRS), $43.3 million in Parexel Consulting and Medical Communications Services (PCMS), and $49.3 million in Perceptive Informatics. New business gains have led to increased hiring and other expenditures, reducing operating margins.